5 December 2012
EMA/638304/2008
Human Medicines Development and Evaluation

Paediatric Committee (PDCO)

Minutes of the 07-09 November 2012 meeting

Chair: Daniel Brasseur

I Introduction

I.1 Adoption of the minutes from previous meeting

Adopted

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.2 Adoption of the Agenda

Adopted with modifications

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.3 Declaration of Conflict of Interest

See Annex I

I.4 External attendance

Please refer to the November PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the November PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the November PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed 66 procedures in total[1], of which:

- 27 paediatric investigation plan applications;
- 8 product-specific waiver applications;
- 5 compliance check procedures (interim and final);
- 26 requests for modifications of an agreed paediatric investigation plan.

IV Nomination of Rapporteurs and Peer reviewers

• List of letters of intent received for submission of applications with start of procedure January 2012[1] for Nomination of Rapporteur and Peer reviewer • Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	The PDCO approved the lists of Rapporteurs and Peer Reviewers.

V Update and finalisation of opinions and requests for modification

All opinions taken at this meeting (relating to adoption of opinions, recommendations, requests for modifications and applicability of class waivers) were made in the presence of the required quorum of members.

The opinions adopted during the Paediatric Committee meeting of November are published in the same month's meeting report published in the EMA website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

[1] The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

VI Discussion of the applicability of class waiver

Class waiver number	Active substance	Condition	Outcome (confirmed / not confirmed)
EMEA-48-2012	Nanoliposomal irinotecan (MM-398)	Treatment of adenocarcinoma of the pancreas	Confirmed
EMEA-49-2012	RO5490249 (FCFD4514S)	Treatment of age-related macular degeneration (AMD)	Confirmed
EMEA-50-2012	Aleglitazar - RO0728804	Peroxisome proliferator-activated receptor (PPAR)-gamma modulators, including dual and multiple PPAR modulators (e.g., thiazolidinediones, glitazars, triple modulators), in the treatment of type II diabetes mellitus (EMEA/386453/2008)	Confirmed
EMEA-51-2012	Aleglitazar - RO0728804	Treatment of coronary atherosclerosis (EMA/973755/2011)	Confirmed

VII Other topics

Guidelines	
Guideline on Pharmaceutical Development of Medicines for Paediatric Use	The latest draft of the guideline after review of comments collected during the public consultation period was presented to the PDCO. The developers propose to go through an additional short consultation period with focus on 3 sections of the guideline that have been substantially revised since the previous version.
Advice to EC on revised* Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies☐	The PDCO briefly discussed the latest adjustments to the proposed revised version of the Guideline. It was agreed that the latest draft will be submitted to PDCO members for adoption in December.
Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia*	The PDCO adopted the guideline with comments.
Concept paper* on the need for a paediatric addendum to the Draft guideline on clinical investigation of medicinal products for the treatment of acute heart failure	The PDCO adopted the concept paper. The Committee members expressed the view that there is also a need for paediatric addendum covering the problems related to clinical trials in paediatric chronic heart failure.

Draft concept paper on collection of pregnancy data for new or commonly used drugs during pregnancy*	A draft concept paper outlining the process to select drugs that would require collection of pregnancy data was presented to the CHMP ORGAM meeting and to the PDCO. A small group of CHMP and PDCO members will be formed to further evaluate the needs for such concept paper.
Working groups and breakout sessions	
Formulation	No non-product related issues where reported to the Committee.
Non-Clinical	No non-product related issues where reported to the Committee.
Extrapolation	N/A.
Oncology	Non-product related issues: Discussion on interactions with stakeholders and on the draft model oncology PIPs*.
Paediatric inventory	Discussion on the current therapeutic area (infectious diseases). The draft list of Inventory of Paediatric Medicines for the therapeutic area of Infectious Diseases* will be sent to the PDCO in the post-mail. The working group discussed the comments received during the consultation phase regarding the Inventory of Paediatric Medicines for the therapeutic area of Cardiovascular diseases. The draft list for the new therapeutic area, Nephrology will be prepared for discussing next month.
Strategy for development of medicinal products for the condition asthma*	This topic was postponed to the December meeting.
Good clinical practice (GCP) inspections in paediatric clinical trials	This breakout session was organised to explore potential specific criteria for performing GCP inspections in paediatric clinical trials. A draft document is being written on the topic.
Article 6.1(J) of the Paediatric Regulation (The Paediatric Committee shall advise the Agency and the Commission regarding the communication of arrangements available for conducting research into medicinal products for use in the paediatric population.)	In a breakout session PDCO members expressed their ideas how communication should be improved on a European and national level in order to promote paediatric clinical research. A document will be drafted to reflect these recommendations.

Other topics	
Feedback of the paediatric anticoagulant therapy expert meeting held at the European Medicines Agency on 6 November 2012*	Postponed. The meeting report* and presentations* will be published on EMA website when the report is final.
Inventory of paediatric medicines: Infectious diseases therapeutic area*	The draft list of Inventory of Paediatric Medicines* for the therapeutic area of Infectious Diseases was discussed at the PDCO and the list will be adopted in the December meeting.
Review of the EMA decision on the list of class waivers	The PDCO progressed in the discussion of the conditions that are covered by the EMA Decision granting a class waiver for conditions (CW/1/2011) with a trend for an opinion to revoke the waivers.
Revision of the standard PIP on allergen	The PDCO members discussed the European Allergen Manufacturer Group (EAMG) proposals for alternate study designs and Standard Allergen PIP revision in the presence of Paul-Ehrlich-Institut (PEI) representatives. A working group was established for further discussions and elaboration of a counter-proposal.
European Medicines Agency policy on changes in scope of paediatric investigation plan (PIP) decisions: Procedure to confirm the inclusion of an indication within a condition	The EMA received the first request for confirmation of the inclusion of an indication within a condition for golimumab, EMA decision P/197/2011, PIP number EMEA-000265-PIP01-08-M02. The Committee was of the opinion that the new proposed indication, “treatment of non-radiographic axial spondyloarthiritis” does not fall under the scope of the EMA decision.
Model oncology PIPs*: Model rhabdomyosarcoma PIP for adoption*	The latest version of this draft document was discussed and in order to consider recent comment, adoption was postponed to December.
Update on EnprEMA activities: Feedback from coordinating group	On 24 October the Coordinating Group convened via teleconference to receive an update on EnprEMA activities: Emerging networks: Cardiology: the European Association of Paediatric Cardiologists (EAPC) has agreed to create a working group on clinical trials and to arrange a face-to-face meeting in the next few months as well as a larger meeting at the EAPC annual conference in London in spring 2013. A call for interest for becoming a participating centre will be advertised to all EAPC members. Gastroenterology: The United European Gastroenterology approved a bid for funding to develop a European paediatric gastroenterology clinical trial network. Diabetes: two meetings with 27 interested participants from various European countries, including 1 representative from ESPE and 4 industry representatives took already place to

	prepare creation of (EnprEMA) European Children and Adolescent Diabetes and Endocrine Trials Network. A workshop on t2DM PIPs with academia, PDCO members, Pharma Industry & Patients Rep, will be held at the Agency on 25th Feb 2013. Potential development of a European wide network within the European College of Neuropsychopharmacology. The model PIP on rhadomyosarcoma was presented. It was discussed that EnprEMA experts in a specific research field should get involved at an early stage during the development of guidelines and comment on them so that different views are shared between experts to globally improve the drug development in children. An outline of the development strategy for asthma medication in children was presented by the PDCO representative. It was agreed that EnprEMA experts should receive the draft document for comments before the next discussion on the strategy takes place at the informal PDCO meeting. All EnprEMA members will be approached to forward details of current activities and planned developments aimed at raising awareness in patients/parents on the need for clinical trials and for increased participation in research trials. CG members were asked to review the published EMA list of class waivers and comment if they see how the waived "adult" diseases and paediatric diseases could be linked by making reference to innovative disease classifications, by any recent scientific findings on biological similarities or characteristics, or by providing examples of medicines which are used in adults for the currently waived conditions but due to their mode of action could be useful in paediatric conditions. EMA Healthcare Professionals Working Party asked to have one representative as observing member of CG in order to improve communication and dissemination of information across learned societies of various health care professionals, including nurses. No objections from CG members were noted. However, a representative of the CG member should also be considered as an observer at HPWP meeting as this may be a more efficient way of relaying areas of concern relevant to children. EnprEMA plans to submit corporate response to the Public consultation on the impact of the European Regulation on medicinal products for paediatric use.

CHMP Safety Working Party's response to the PDCO regarding the use of PEGylated drug products in the paediatric population[2]	The PDCO was informed about the adoption by CHMP of the "Safety Working Party's response to the PDCO regarding the use of PEGylated drug products in the paediatric population". The main concerns and recommendation to applicants were summarized. The document has now been published on the EMA website.

VIII Any other business

Note on access to documents

Documents marked with an asterisk* in these minutes cannot be released at present as they are currently in draft format. They will become public when adopted in their final form.

[2] Post meeting note: This document was published on the EMA website on 23 November 2012.

Annex I to the Minutes of the PDCO of November 2012

Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

Member, alternate, expert name	Outcome restriction following evaluation of electronic evaluation form	Topics on the current Committee Agenda for which this restriction applies
Adriana Ceci	Restriction level XR	EMEA-000019-PIP08-12
Adriana Ceci	Restriction level XR	EMEA-001260-PIP01-11
Carine de Beaufort	Restriction level XR	EMEA-49-2012
Carine de Beaufort	Restriction level XR	EMEA-50-2012
Carine de Beaufort	Restriction level XR	EMEA-51-2012
Christoph Male	Restriction level DP	EMEA-000778-PIP02-12
Christoph Male	Restriction level DP	EMEA-001281-PIP01-12
Christoph Male	Restriction level XP	EMEA-000183-PIP02-12
Dobrin Konstantinov	Restriction level XP	EMEA-000468-PIP02-12
Gerard Pons	Restriction level 3	EMEA-000019-PIP08-12
Jaroslav Sterba	Restriction level XP	EMEA-000468-PIP02-12
Jaroslav Sterba	Restriction level XP	EMEA-001259-PIP01-11
Matthias Keller	Restriction level DP	EMEA-000018-PIP01-07-M05
Matthias Keller	Restriction level DP	EMEA-000325-PIP01-08-M01
Matthias Keller	Restriction level DP	EMEA-000485-PIP01-08-M01
Matthias Keller	Restriction level DP	EMEA-000486-PIP01-08-M01
Matthias Keller	Restriction level DP	EMEA-000494-PIP01-08-M05
Matthias Keller	Restriction level DP	EMEA-000495-PIP01-08-M05
Matthias Keller	Restriction level DP	EMEA-001281-PIP01-12
Michal Odermarsky	Restriction level XP	EMEA-000804-PIP01-09-M01

Member, alternate, expert name	Outcome restriction following evaluation of electronic evaluation form	Topics on the current Committee Agenda for which this restriction applies
Paolo Rossi	Restriction level 4	EMEA-001290-PIP01-12
Peter Szitanyi	Restriction level DP	EMEA-001353-PIP01-12
Romaldas Maciulatis	Restriction level XR	EMEA-000726-PIP01-09-M01
Romaldas Maciulatis	Restriction level XR	EMEA-49-2012
Romaldas Maciulatis	Restriction level XR	EMEA-50-2012
Romaldas Maciulatis	Restriction level XR	EMEA-51-2012

Note: the procedures identified in the table above are on-going and therefore considered commercially confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

Restriction levels:

The European Medicines Agency recently reviewed and updated the coding used in the evaluation of the conflict of interest. There will be a short transition period when both codes will be in used until procedures evaluated under the previous code have been completed.

Evaluation of the conflict of interest – Previous code	
Outcome	Impact
1	No involvement in activity
2	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.
3	Where Individual product involvement is declared: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication, i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products.
4	Where Individual product involvement is declared: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product, i.e. no part in final deliberations and voting as appropriate as regards these medicinal product.
Evaluation of the conflict of interest – New code	
Outcome	Impact
R-P	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.

XP	Where Individual product involvement is declared - PRODUCT INDICATION: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products - [Cannot act as Rapporteur for development of guidelines in concerned therapeutic area].
XC	Where cross product / general involvement is declared - COMPANY: - No involvement (as outlined above) with respect to products from the specified company. - Cannot act as Rapporteur for products from the relevant company(ies).
DP	Where Individual product involvement is declared - PRODUCT INDICATION: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product i.e. no part in final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products.
DC	Where cross product / general involvement is declared - COMPANY: - Involvement in discussions only with respect to products from the specified company. - Cannot act as Rapporteur on products from the relevant company(ies).
XR	Committee member cannot act as Rapporteur or Peer reviewer in relation to any medicinal product from the relevant company.
R-C	To be replaced for the discussions, final deliberations and voting as appropriate in relation to any medicinal product from the relevant company

Annex II to the Minutes of the PDCO of November 2012

List of Participants

Chair

Daniel BRASSEUR

Vice-chair

Dirk MENTZER

Members appointed by Member States or CHMP

Christoph MALE	Austria
Koenraad NORGA	Belgium
Dobrin KONSTANTINOV	Bulgaria
Jaroslav STERBA	Czech Republic
Marianne ORHOLM	Denmark
Irja LUTSAR	Estonia
Pirjo LAITINEN-PARKONNEN	Finland
Gerard PONS	France
Dirk MENTZER	Germany
Agnes GYURASICS	Hungary
Gylfi OSKARSSON	Iceland
Kevin CONNOLLY	Ireland
Dina APELE-FREMIANE	Latvia
Carine de BEAUFORT	Luxembourg
Hendrik van den BERG	The Netherlands
Siri WANG	Norway
Marek MIGDAL	Poland
Helena FONSECA	Portugal
Nela VILCEANU	Romania
Vlasta KAKOSOVA	Slovak Republic
Janez JAZBEC	Slovenia
Fernando DE ANDRÉS TRELLES	Spain

Marta GRANSTRÖM	Sweden
Julia DUNNE	United Kingdom

Alternates appointed by Member States or CHMP

Karl Heinz HUEMER	Austria
Jacqueline CARLEER	Belgium
Margarita GUIZOVA	Bulgaria
Ann Marie KAUKONEN	Finland
Sylvie BENCHETRIT	France
Birka LEHMANN	Germany
Brian AYLWARD	Ireland
Francesca ROCCHI	Italy
Herbert LENICKER	Malta
Johannes TAMINIAU	The Netherlands
Ine Skottheim RUSTEN	Norway
Jolanda WITKOWSKA-OZOGOWSKA	Poland
Hugo TAVARES	Portugal
Maria Jesus FERNANDEZ CORTIZO	Spain
Viveca Lena ODLIND	Sweden

Members representing patients' organisations

Alternates representing patients' organisations

Gerlind BODE

Members representing health care professionals

Adriana CECI

Anthony James NUNN

Alternates representing health care professionals

Paolo PAOLUCCI

Experts

Peter BAUER	Medical statistician

Observers

European Medicines Agency

Agnes SAINT RAYMOND	Head of Sector, Human Medicines Special Areas

Paolo TOMASI	Head of Section, Paediatric Medicines
Sophie OLIVIER	Scientific Administrator, Paediatric Medicines
Anne-Sophie HENRY-EUDE	Scientific Administrator, Paediatric Medicines
Almudena SAIZ HERRANZ	Scientific Administrator, Paediatric Medicines
Benjamin PELLE	Scientific Administrator, Paediatric Medicines
Blanca QUIJANO RUIZ	Scientific Administrator, Paediatric Medicines
Cecile OLLIVIER	Scientific Administrator, Paediatric Medicines
Dobromir PENKOV	Scientific Administrator, Paediatric Medicines
Elin Haf DAVIES	Scientific Administrator, Paediatric Medicines
Giovanni LESA	Scientific Administrator, Paediatric Medicines
Gunter EGGER	Scientific Administrator, Paediatric Medicines
Irmgard EICHLER	Scientific Administrator, Paediatric Medicines
Janina KARRES	Scientific Administrator, Paediatric Medicines
Peter KÁROLYI	Scientific Administrator, Paediatric Medicines
Ralf HEROLD	Scientific Administrator, Paediatric Medicines
Ralph BAX	Scientific Administrator, Paediatric Medicines
Richard VESELY	Scientific Administrator, Paediatric Medicines
Thorsten OLSKI	Scientific Administrator, Paediatric Medicines
Alessandro JENKNER	National Expert on Secondment, Paediatric Medicines
Cristina BEJNARIU	Trainee
Aurelie HERVIEU	Assistant, Paediatric Medicines
Isabel PEREZ	Assistant, Paediatric Medicines
Anna MESTERHAZY	Assistant, Paediatric Medicines